Registration Form
More information about the registration form
.
I. PERSON AND ORGANISATION DETAILS

Surname, Name, Title of the researcher  (mandatory field):


Name of the organisation  (mandatory field):


Name of the research unit:


Country:


Web page:


Telephone number/Fax  (mandatory field):


E-mail  (mandatory field):


Field of research  (mandatory field):



II. FRAMEWORK PROGRAMS AND EUROPEAN PROJECTS

Former participation of the scientist in an Framework Program European Project(s)?  




III. EXPERTISE / INTEREST OFFERED

Keywords specifying the expertise that you are able to offer:


Description of the expertise you are able to offer (max 1000 characters):


Interest offered:

 Research     Demonstration     Training     Technology     Dissemination

If other interest offered, please specify here:


Proposed role in the project:

 Coordinator     Work package leader     Partner     Other role   


Call Topics - topics of interest for the next FP7 HEALTH Call(s)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.1. HIGH-THROUGHPUT RESEARCH

HEALTH.2011.1.1-1: S.M.E. targeted research for developing tools and technologies for high-throughput research
HEALTH.2011.1.1-2: Genome-based biomarkers for patient stratification and pharmacogenomic strategies
HEALTH.2011.1.1-3: High-throughput proteomics for human health and disease

1.2 DETECTION, DIAGNOSIS AND MONITORING

Closed in WP 2011

1.3 SUITABILITY, SAFETY, EFFICIACY OF THERAPIES

Closed in WP 2011

1.4. INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

HEALTH.2010.1.4-1: Regenerative medicine clinical trials
HEALTH.2011.1.4-2: Tools, technologies and devices for application in regenerative medicine
HEALTH.2010.1.4-3: Development and production of new, high-affinity protein scaffolds for therapeutic use
HEALTH.2010.1.4-4: High impact initiative for better immunisation
HEALTH.2010.1.4-5: New therapeutic approaches in chronic inflammatory and autoimmune diseases

Which kind of research in this area do you think that the EU needs to emphasise, as compared to the topics above? Please specify (max 1000 characters):


2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

2.1.1: Large-scale data gathering

HEALTH.2011.2.1.1-1: High impact initiative on the human epigenome
HEALTH.2011.2.1.1-2: Proteins and their interactions in health and disease
HEALTH.2011.2.1.2-3: Large-scale genomics approaches to identify host determinants of infectious diseases
HEALTH.2011.2.1.1-4: Population genetics studies on cardio-metabolic disorders in EU/AC and EECA populations

2.1.2: Systems biology

Closed in WP 2011

2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

2.2.1: Brain and brain-related diseases

HEALTH.2011.2.2.1-1: Investigator-driven clinical trials for childhood-onset neurodegenerative diseases
HEALTH.2011.2.2.1-2: Understanding the role of neuroinflammation in neurodegenerative diseases
HEALTH.2011.2.2.1-3: Addictive and/or compulsive behavior in children and adolescents: translating pre-clinical results into therapies
HEALTH.2011.2.2.1-4: Creating clinical and molecular tools for experimental therapy of paediatric neurodegenerative disorders causing childhood dementia in Europe and India
HEALTH.2011.2.2.1-5: ERA-Net on disease-related neurosciences

2.2.2: Human development and ageing

HEALTH.2011.2.2.2-1: Investigator-driven clinical trials for therapeutic interventions in the elderly populations
HEALTH.2011.2.2.2-2: Linking human development and ageing

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

2.3.1: Anti-microbial drug resistance

HEALTH.2011.2.3.1-1: Investigator-driven clinical trials of off-patent antibiotics
HEALTH.2011.2.3.1-2: Multi-disciplinary research on the evolution and transfer of antibiotic resistance
HEALTH.2011.2.3.1-3: Management of Gram negative multi-drug resistant infections
HEALTH.2011.2.3.1-4: Development of multi-analyte diagnostic tests
HEALTH.2011.2.3.1-5: Development of tools to control microbial biofilms with relevance to clinical drug resistance

2.3.2: HIV/AIDS, malaria and tuberculosis

Closed in WP 2011

2.3.3: Potentially new and re-emerging epidemics

HEALTH.2011.2.3.3-1: Identification of factors promoting the emergence of pathogens with human pandemic potential from pathogens with a zoonotic background and related prevention strategies
HEALTH.2011.2.3.3-2: control of Dengue fever under changing climatic conditions
HEALTH.2011.2.3.3-3: FeverDevelopment of an evidence-based behavioural and communication package to respond to major epidemic outbreaks

2.3.4: Neglected infectious diseases

Closed in WP 2011

2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

2.4.1: Cancer

HEALTH.2011.2.4.1-1: Investigator-driven, treatment trials for rare cancers
HEALTH.2011.2.4.1-2: Translational research on cancers with poor diagnosis
HEALTH.2011.2.4.1-3: Epidemiology and aetiology of infection-related cancers

2.4.2: Cardiovascular diseases

HEALTH.2011.2.4.2-1: Investigator driven clinical trials for the management of cardiovascular diseases
HEALTH.2011.2.4.2-2: Evaluation and validation studies

2.4.3: Diabetes and obesity

HEALTH.2011.2.4.3-1: Investigator-driven clinical trials to reduce diabetes complications
HEALTH.2010.2.4.3-2: Development of novel treatment strategies based on knowledge of cellular dysfunction
HEALTH.2010.2.4.3-4: Genetic and environmental factors in obesity and/or diabetes in specific populations
HEALTH.2010.2.4.3-5: ERA-Net on diabetes prevention and treatment

2.4.4: Rare diseases

Closed in WP 2011

2.4.5: Other chronic diseases

Closed in WP 2011

Which kind of research in this area do you think that the EU needs to emphasise, as compared to the topics above? Please specify (max 1000 characters):


3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS

3.1. TRANSLATING CLINICAL RESEARCH INTO PRACTICE

Closed in WP 2011

3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS

Closed in WP 2011

3.3. HEALTH PROMOTION

HEALTH.2011.3.3-1: Developing methodologies to reduce inequities in the determinants of health
HEALTH.2011.3.3-2: Analysis of integrated strategies for sustainable behaviour change
HEALTH.2011.3.3-3: Developing and implementing methods for the transfer of research into policy in the fields of Health promotion and disease prevention
HEALTH.2011.3.3-4: A road-map for mental health research in Europe

3.4. INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS

HEALTH.2011.3.4-1: Develop and assessment of comprehensive and integrated interventions and programmes to improve reproductive health and health equity
HEALTH.2011.3.4-2: Building sustainable capacity for research for health and its social determinants in low & middle income countries
HEALTH.2011.3.4-3: Multilateral cooperation between Europe, Africa and Latin America on public health and health services research

Which kind of research in this area do you think that the EU needs to emphasise, as compared to the topics above? Please specify (max 1000 characters):


4. OTHER ACTIONS ACROSS THE HEALTH THEME

4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME

HEALTH.2011.4.1-1: Networking of major research institutions to coordinate communication actions aimed at the media and the general public
HEALTH.2011.4.1-2: Targeting publication bias
HEALTH.2011.4.1-3: Linking EU and Latin American policy making institutions in the field of health research
HEALTH.2011.4.1-4: Organisation of supporting actions and events related to the Presidency of the European Union

4.2. RESPONDING TO EU POLICY NEEDS

HEALTH.2011.4.2-1: Investigator-driven clinical trials on off-patent medicines for children
HEALTH.2011.4.2-2: Adverse drug reaction research
HEALTH.2011.4.2-3: New methodologies for clinical trials in personalised medicine

Which kind of research in this area do you think that the EU needs to emphasise, as compared to the topics above? Please specify (max 1000 characters):



IV. EXPECTATIONS

Term Commitment:  

Expected results for your organisation. Please specify (max 1000 characters):



V. DETAILS ON RESEARCH PARTNER

Surname, Name, Title of the researcher  (mandatory field):


Name of the organisation:


Name of the research unit:


His/her e-mail  (mandatory field):










@2009, EECA link